New Biomarkers and Therapeutics Show Potential in Still's Disease
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…
View Resource
No Great Options for Treating VEXAS
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs…
View Resource
World Changers (3.14.2025)
Dr Jack Cush and his podcast friends are out to change the world. Here…
View Resource
Emapalumab for the treatment of macrophage activation syndrome
Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a…
View Resource
Rheumatic Associated Macrophage Activation Syndrome
Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and…
View Resource
Still’s Disease FAQs
What is the classic ‘triad’ of Still’s disease? Does it affect males and females…
View Resource
ACR 2022 Appraisal, Praise & Critique (11.18.2022)
It was great to be back at an ACR annual meeting, this one in…
View Resource
Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…
View Resource
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
Editor’s note: This article originally appeared March 12, 2024, and is being shared again…
View Resource
ERA, APPs, & Alpha GAL (3.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on…
View Resource